抗肿瘤药培美曲塞的临床应用研究近况

Recent Studies on Clinical Application of Anticancer Agent Pemetrexed

抗肿瘤药培美曲塞能抑制叶酸代谢所依赖的几个关键酶的活性,从而多靶点、多方位地抑制肿瘤细胞的生长。临床前研究与临床试验都表明,培美曲塞能抗多种肿瘤,且与许多其它抗癌药有协同增效作用。虽然目前该药仅被批准用于恶性胸膜间皮瘤和非小细胞肺癌,但其在临床上还有更大的潜力。介绍近年来培美曲塞的临床应用研究情况,包括与铂络合物、吉西他滨、长春瑞滨、紫杉醇和伊立替康等药物联用的临床疗效以及单独或与其它抗癌药联用于治疗头颈部癌、乳腺癌、胃癌、肠癌及膀胱癌等的初步临床研究结果。

Pemetrexed, a novel anti-tumor drug, could inhibit several folate-requiring key enzymes in purine synthesis, consequently block growth and multiplication of carcinoma cell. The results of preclinical investigation and clinical trials have shown that pemetrexed has a broad antitumor spectra and sinergistic effects together with other anticancer agents. Although pemetrexed was approved by FDA only for the indications of malignant pleural mesothelioma and non-small-cell lung cancer, it is more promising in clinic in future. The recent clinical studies on pemetrexed were briefly described in this paper, including the clinical response rate of the patients who were administered with pemetrexed alone or combined with other antineoplastic drugs, such as platinum complex （cisplatin, carboplatin and oxaliptatin）, gemcitabine, doxorubicin, paclitaxel, irinotecan and vinorelbine. The primary treatment results of squamous-cell carcinoma of head and neck, gastric cancer, colon cancer, breast cancer, cervical cancer, bladder cancer and pancreatic cancer were also introduced.